Quantitative Biology. Delivered.
RNA • DNA • Protein
Over the last 10 years, the Panomics Division of Affymetrix (Panomics) has been dedicated to providing innovative, assay, tools and educational resources for cancer and infectious disease research, exploration and discovery of mechanisms and interactions within the immune system and throughout all of the various phases of the drug discovery and development process utilizing branched DNA (bDNA) technology.
With an extensive and expansive portfolio of QuantiGene and Procarta assays, Panomics has been able to aid customers with the efficiency, performance and accuracy of their assays. These products include single and multiplex DNA and RNA detection assays compatible with cells, FFPE tissues, and tissue lysates.
Panomics innovative tools and assays are unique solutions that are applied on a regular basis in cancer research today from discovery to clinical research and validation.
QuantiGene ViewRNA Assay
An assay for mRNA in situ analysis
In situ hybridization techniques are used to visualize DNA or localized RNAs within cells. However the in situ analysis of RNA in particular has always been limited by low sensitivity, complicated workflow, robustness and the inability to perform multiplex analysis. QuantiGene ViewRNA is a novel mRNA in situ hybridization solution, based on patent-pending probe set design and proprietary signal amplification methodology, that offers single-copy mRNA sensitivity in single cells in a multiplex assay format. This new technology enables transcriptional profiling of individual cells within a population, and has broad applicability in research and industry. Some of the many applications include biomarker validation testing, stem cell characterization, differentiation and quality control, viral host-cell interactions, validation of microarray gene expression results and in vitro and in vivo RNAi delivery and knockdown.
The automation-friendly, simple assay workflow for cultured cells is suitable for high-throughput applications such as phenotypic or reporter gene screening. QuantiGene ViewRNA for tissues, formalin-fixed, paraffin-embedded (FFPE) or cryogenic sections, is a practical alternative to immunohistochemistry (IHC) where antibodies are either unavailable or unreliable in the experimental system under investigation.
QuantiGene 2.0 Reagent System
Gene Expression without the limitations
QuantiGene assays bring the power of branched DNA (bDNA) technology to basic and pre-clinical research. The bDNA assay is a sandwich nucleic acid hybridization method that uses bDNA molecules to amplify signal from captured target RNA. bDNA technology forms the basis of the FDA-approved clinical diagnostic VERSANT 3.0 assays for HIV, HCV and HBV viral load, that are offered commercially by Siemens and have been in use for over a decade. Another advantage of bDNA assays is that RNA is measured directly from the sample source, without RNA purification or enzymatic manipulation, thereby avoiding inefficiencies and variability introduced by or errors inherent to these processes.
QuantiGene Plex 2.0 Reagent System
Measure multiple RNA targets simultaneously
QuantiGene Plex 2.0 assays combine branched DNA (bDNA) signal amplification technology and xMAP® (multi-analyte profiling) beads to enable simultaneous quantification of multiple RNA targets directly from cultured cell or whole blood lysates; fresh, frozen or formalin-fixed, paraffin-embedded (FFPE) tissue homogenates; or purified RNA preparations. Branched DNA technology is a sandwich nucleic acid hybridization assay that provides a unique approach for RNA detection and quantification by amplifying the reporter signal rather than the sequence. By measuring the RNA at the sample source, the assay avoids variations or errors inherent to extraction and amplification of target sequences. The xMAP system, developed by Luminex Corp, combines flow cytometry, fluorescent-dyed microspheres (beads), lasers and digital signal processing to effectively allow multiplexing of up to 100 unique assays within a single sample.
Branched DNA technology is the basis of clinically proven viral load tests commercialized by Siemens, as VERSANT HIV-1 3.0, HCV 3.0 and HBV assays, and has been in use for over a decade. Offered by Panomics, QuantiGene and QuantiGene Plex assays are now widely used for basic and pre-clinical research, in applications encompassing biomarker discovery, secondary screening, validation of microarray data, quantification of RNAi knockdown and predictive toxicology.
Procarta Cytokine Assays
Cell signalling pathway monitoring
Procarta® Protein Profiling Assays enable simultaneous monitoring of inter- and intracellular protein signaling pathways in a 96-well plate format. Panomics is developing a broad family of assays designed to measure protein expression and monitor protein modification/activation states in diverse matrices.
Procarta protein assays use the xMAP® technology (mutli-analyte profiling beads) to enable the detection and quantitation of multiple protein targets simultaneously. The xMAP system combines a flow cytometer, fluorescent-dyed microspheres (beads), lasers and digital signal processing to effectively allow multiplexing of up to 100 unique assays within a single sample. The Procarta assay kits are compatible with all Luminex and Luminex-based instruments currently available.
About Panomics and Affymetrix
Panomics is a privately-held life science company that offers a platform of reagents and products that enable the multiplex measurement of molecular events, such as intracellular pathway analysis, cell signaling and gene expression profiling, in a quantitative and scalable manner. Panomics has grown rapidly on the value of its proprietary branched DNA technology for gene expression analysis in cell-based assays, as well as our signal transduction and transcription factor assays. Formerly named Genospectra, Panomics was founded in 2000 and is based in Fremont, CA.
Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.
Today, Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,800 systems have been shipped around the world and more than 14,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia.